Zhijuan Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhijuan Lin has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Bing Xu
Department of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, China
3 shared publications Xing Chen
3 shared publicationsZhifeng Li
3 shared publicationsBing Xu
Department of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
2 shared publicationsLong Liu
2 shared publicationsThe First Affiliated Hospital Of Xiamen Hospital
2 shared publications
Latest Publications
- 5 March 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 130, 111765
Lactate acid promotes PD-1+ Tregs accumulation in the bone marrow with high tumor burden of Acute myeloid leukemia
- 5 March 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 130, 111765
Lactate acid promotes PD-1+ Tregs accumulation in the bone marrow with high tumor burden of Acute myeloid leukemia
- 6 January 2022
- Published by American Society of Hematology in Blood
- Vol. 139 (1) , 59-72
RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway
Proteasome inhibitors (PIs) such as bortezomib (Btz) and carfilzomib (Cfz) are highly efficacious for patients with multiple myeloma (MM). However, relapses are frequent, and acquired resistance to PI treatment emerges in most patients. Here, we performed a high-throughput screen of 1855 Food and Drug Administration (FDA)-approved drugs and identified all-trans retinoic acid (ATRA), which alone has no antimyeloma effect, as a potent drug that enhanced MM sensitivity to Cfz-induced cytotoxicity and resensitized Cfz-resistant MM cells to Cfz in vitro. ATRA activated retinoic acid receptor (RAR)γ and interferon-β response pathway, leading to upregulated expression of IRF1. IRF1 in turn initiated the transcription of OAS1, which synthesized 2-5A upon binding to double-stranded RNA (dsRNA) induced by Cfz and resulted in cellular RNA degradation by RNase L and cell death. Similar to ATRA, BMS961, a selective RARγ agonist, could also (re)sensitize MM cells to Cfz in vitro, and both ATRA and BMS961 significantly enhanced the therapeutic effects of Cfz in established MM in vivo. In support of these findings, analyses of large datasets of patients’ gene profiling showed a strong and positive correlation between RARγ and OAS1 expression and patient’s response to PI treatment. Thus, this study highlights the potential for RARγ agonists to sensitize and overcome MM resistance to Cfz treatment in patients.
- 6 January 2022
- Published by American Society of Hematology in Blood
- Vol. 139 (1) , 59-72
RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway
Proteasome inhibitors (PIs) such as bortezomib (Btz) and carfilzomib (Cfz) are highly efficacious for patients with multiple myeloma (MM). However, relapses are frequent, and acquired resistance to PI treatment emerges in most patients. Here, we performed a high-throughput screen of 1855 Food and Drug Administration (FDA)-approved drugs and identified all-trans retinoic acid (ATRA), which alone has no antimyeloma effect, as a potent drug that enhanced MM sensitivity to Cfz-induced cytotoxicity and resensitized Cfz-resistant MM cells to Cfz in vitro. ATRA activated retinoic acid receptor (RAR)γ and interferon-β response pathway, leading to upregulated expression of IRF1. IRF1 in turn initiated the transcription of OAS1, which synthesized 2-5A upon binding to double-stranded RNA (dsRNA) induced by Cfz and resulted in cellular RNA degradation by RNase L and cell death. Similar to ATRA, BMS961, a selective RARγ agonist, could also (re)sensitize MM cells to Cfz in vitro, and both ATRA and BMS961 significantly enhanced the therapeutic effects of Cfz in established MM in vivo. In support of these findings, analyses of large datasets of patients’ gene profiling showed a strong and positive correlation between RARγ and OAS1 expression and patient’s response to PI treatment. Thus, this study highlights the potential for RARγ agonists to sensitize and overcome MM resistance to Cfz treatment in patients.
- 29 December 2021
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
The role of Central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: a network meta-analysis
INPLASY2021120131 The role of Central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: a network meta-analysis Keywords: central nervous system (CNS) relapses; diffus…
- 29 December 2021
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
The role of Central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: a network meta-analysis
INPLASY2021120131 The role of Central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: a network meta-analysis Keywords: central nervous system (CNS) relapses; diffus…
- 30 November 2021
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Chemo-Free Treatments in Relapsed and/or Refractory Follicular Lymphoma: A Network Meta-Analysis
Review question / Objective: FL is the most common indolent B cell lymphoma worldwide and patients with FL always have long term survival. However, advanced FL remains incurable and there is no universal agreement on optimal regimen to manage relapsed FL. Condition being studied: The efficacy of chemo-free regimens, including CD20 antibodies and targeted agents, in relapsed and/or refractory Follicular lymphoma. Information sources: We used the MEDLINE, Embase, and Cochrane Library databases to search the RCTs met our selection criteria. We also searched clinicalTrials.gov and the international clinical trial registry platform for completed and ongoing trials. In addition, we searched abstracts that published on American Society of Hematology (ASH), The European Hematology Association (EHA) or American Society of Clinical Oncology (ASCO) meetings.
- 30 November 2021
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Chemo-Free Treatments in Relapsed and/or Refractory Follicular Lymphoma: A Network Meta-Analysis
Review question / Objective: FL is the most common indolent B cell lymphoma worldwide and patients with FL always have long term survival. However, advanced FL remains incurable and there is no universal agreement on optimal regimen to manage relapsed FL. Condition being studied: The efficacy of chemo-free regimens, including CD20 antibodies and targeted agents, in relapsed and/or refractory Follicular lymphoma. Information sources: We used the MEDLINE, Embase, and Cochrane Library databases to search the RCTs met our selection criteria. We also searched clinicalTrials.gov and the international clinical trial registry platform for completed and ongoing trials. In addition, we searched abstracts that published on American Society of Hematology (ASH), The European Hematology Association (EHA) or American Society of Clinical Oncology (ASCO) meetings.
- 1 October 2021
- Published by Elsevier in Current Problems in Cancer
- Vol. 45 (5) , 100728
Secondary myeloma in patients with chronic lymphoblastic leukemia: A case report and analysis of data from SEER database
- 1 October 2021
- Published by Elsevier in Current Problems in Cancer
- Vol. 45 (5) , 100728
Secondary myeloma in patients with chronic lymphoblastic leukemia: A case report and analysis of data from SEER database